Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY
Harmony Biosciences — Q2 2021 Earnings Presentation
15 slides from Harmony Biosciences's earnings presentation, Aug 11, 2021
Slide 1: Harmony Biosciences Q2 2021 Financial and Business Update
Exhibit 99.2 Harmony Biosciences Q2 2021 Financial and Business Update August 10, 2021Exhibit 99.2 Harmony Biosciences Q2 2021 Financial and Business Update August 10, 2021
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes forward‐ looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, In
Slide 3: Harmony's Strategy for Growth
Harmony’s Strategy for Growth Expand Optimize Acquire ® WAKIX Clinical New Commercial Utility of Assets Launch WAKIX 3Harmony’s Strategy for Growth Expand Optimize Acquire ® WAKIX Clinical New Commercial Utility of Assets Launch WAKIX 3
Slide 4: Q2 2021 WAKIX Revenue Performance
Q2 2021 WAKIX Revenue Performance Continued Growth with Q2 Revenue of $73.8M $73.8 2Q21 2Q21 2Q20 1Q21 2Q21 vs. vs. $59.7 1Q21 2Q20 $56.3 $38.0 $59.7 $73.8 23.6% 94% $45.6 $38.0 Strong Revenue Growth in Q2 2021 § 23.6% growth Q2 2021 vs. Q1 2021 $19.8 § Over 90% growth Q2 2021 vs. Q2 2020 § Continue
Slide 5: Driving Growth Through Our Launch For WAKIX
Driving Growth Through Our Launch For WAKIX Q2 2021 Performance Increased Access to HCPs Average # of ~3,200 WAKIX Patients Patient Outreach Programs & Support Of 8,000 unique HCPs have >37% prescribed WAKIX since launch Healthcare Professional Educational Initiatives U.S. Covered Lives With Formula
Slide 6: Core Attributes of WAKIX Product Profile Align with Existing Unmet Needs in Narcolepsy
Core Attributes of WAKIX Product Profile Align with Existing Unmet Needs in Narcolepsy Top Unmet Needs in Narcolepsy * WAKIX (pitolisant) (cited by patients and HCPs) Need for non-scheduled treatment options First and only FDA approved (low/no abuse potential) non-scheduled treatment option for narc
Slide 7: Harmony Development Pipeline
Harmony Development Pipeline 7Harmony Development Pipeline 7
Slide 8: Control Centers for Sleep-Wake Centered in the Hypothalamus
Control Centers for Sleep-Wake Centered in the Hypothalamus (HT) • Main mediators of wakefulness and sleep/wake state stability: • orexin/hypocretin (produced in the Cortex lateral HT) • histamine (produced in the TMN, Prefrontal Cortex also located in the HT) Orexin/ MCH Hypocretin BF (ACh/GABA) •
Slide 9: Orexin and MCH: Opposing Roles in the Hypothalamus Related to Sleep-Wake Function
Orexin and MCH: Opposing Roles in the Hypothalamus Related to Sleep-Wake Function In NT1 with orexin deficiency: Original model of narcolepsy: • imbalance between orexin and MCH, the • imbalance between orexin and GABA, REM generator the NREM sleep generator • MCH goes unchecked causing REM • GABA g
Slide 10: Pre-clinical POC for MCHR1 Antagonism
Pre-clinical POC for MCHR1 Antagonism SLREM: short latency transitions into REM sleep (a feature of NT1) 1. Naganuma et al, NeurobiolDis. 2018; 120, 12. 10 2. Oshio et al. J of NeuroScience. 2013:33;9743.Pre-clinical POC for MCHR1 Antagonism SLREM: short latency transitions into REM sleep (a feature
Slide 11: HBS-102: Next Steps
HBS-102: Next Steps ¾ Demonstrate preclinical POC with HBS-102 in orexin knockout mouse model ¾ Prepare IND then submit to FDA ¾ Initiate Phase 2a proof of concept study once IND opens Become a leading rare neurological disease company with an innovative product portfolio Committed to advancing brea
Slide 12: Strategic Financing Collaboration
Strategic Financing Collaboration $330M of financing and growth capital from Blackstone enables Harmony to expand portfolio of assets in rare, neurological diseases Benefits to Harmony Debt to payoff existing debt $200M facility • Strengthens balance sheet • Access to additional capital to acquire c
Slide 13: Q2 2021 Financial Summary
Q2 2021 Financial Summary (in millions, USD) Three Months Ended June 30, 2021 2020 Net Product Revenues $ 73.8 $ 38.0 Cost of Product Sold 12.7 6.4 Total Operating Expenses $ 37.8 $ 24.2 R&D Expense 6.5 4.2 S&M Expense 17.0 12.4 G&A Expense 14.3 7.6 Net Income available to common $ 14.1 $ (10.5) sto
Slide 14: GAAP vs Non-GAAP Reconciliation
GAAP vs Non-GAAP Reconciliation (in millions, USD) Three Months Ended June 30, 2021 2020 GAAP reported net income (loss) $ 14.1 $ (0) Interest expense / income 7.2 6.9 Taxes 2.0 Depreciation 0.1 0.1 Amortization 4.6 1.9 EBITDA 28.0 8.9 Stock-based compensation expense 3.8 0.6 Loss on debt extinguish
Slide 15: Thank You
Thank You August 10, 2021Thank You August 10, 2021
Harmony Biosciences Holdings — Q2 2021 Earnings Presentation on 6ix